Drugs that contain Eslicarbazepine Acetate
1. List of Aptiom drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9206135 | SUNOVION PHARMS INC | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11364247 | SUNOVION PHARMS INC | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(2 years from now) | |
| US10702536 | SUNOVION PHARMS INC | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(2 years from now) | |
| US10695354 | SUNOVION PHARMS INC | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(2 years from now) | |
| US10675287 | SUNOVION PHARMS INC | Methods of treatment of partial onset seizures using eslicarbazepine acetate |
May, 2025
(2 years from now) | |
| US9643929 | SUNOVION PHARMS INC | Asymmetric catalytic reduction of oxcarbazepine |
Apr, 2026
(3 years from now) | |
| US9763954 | SUNOVION PHARMS INC | Therapeutical uses of eslicarbazepine |
Sep, 2028
(5 years from now) | |
| US9566244 | SUNOVION PHARMS INC | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(5 years from now) | |
| US10912781 | SUNOVION PHARMS INC | Pharmaceutical composition comprising licarbazepine acetate |
Oct, 2028
(5 years from now) | |
| US8372431 | SUNOVION PHARMS INC | Pharmaceutical composition comprising licarbazepine acetate |
Apr, 2030
(7 years from now) | |
| US9750747 | SUNOVION PHARMS INC | Treatments involving eslicarbazepine acetate or eslicarbazepine |
Aug, 2032
(9 years from now) | |
Market Authorisation Date: 08 November, 2013
Treatment: Treatment of partial-onset seizures; Treatment of partial-onset seizures in a patient with refractory partial-onset seizures; Treatment of partial-onset seizures in patients with epilepsy who have been previously treated with oxcarbazepine; Treatment of partial-onset seizures in a patient suffering from or susceptible to absence seizures
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic